JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS^G12C for the Treatment of Solid Tumors

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Tumor resistance to covalent KRAS G12C inhibitors often arises from RAS pathway reactivation.
• Development of novel inhibitors with distinct binding modes is crucial for overcoming resistance mutations.
• Combination treatments are being explored to enhance efficacy and prevent resistance.

Purpose of the Study:

• To introduce JDQ443, an investigational covalent KRAS G12C inhibitor.
• To describe the structure-based drug design and optimization process for JDQ443.
• To present preclinical and early clinical data for JDQ443.

Main Methods:

• Structure-based drug design and optimization of lead compounds.
• Characterization of JDQ443 as a stable atropisomer with a unique chemical structure.
• In vivo pharmacokinetic/pharmacodynamic (PK/PD) studies and xenograft model efficacy assessments.
• Analysis of early phase clinical trial data (NCT04699188).

Main Results:

• JDQ443 exhibits a unique chemical structure with a 5-methylpyrazole core and spiro-azetidine linker.
• The inhibitor demonstrates novel interactions within the KRAS G12C binding pocket, independent of H95.
• Preclinical studies showed in vivo PK/PD activity and dose-dependent antitumor effects in mouse xenografts.
• Early Phase Ib/II clinical trial data for JDQ443 are encouraging.

Conclusions:

• JDQ443 represents a novel covalent KRAS G12C inhibitor with a distinct binding mode.
• Its design addresses potential resistance mechanisms observed with existing therapies.
• Encouraging preclinical and early clinical findings support further development of JDQ443, particularly in combination strategies.